Biotech Values

[ghmm]

NKTR:

Nektar is up again around ~4% so in 2 months and a week or so the stock is up ~50% on really no news (The Q2 report/call was basically uneventful).

While I can't be 100% certain I think its extremely likely related to NKTR-214. The study is open label and should be well into an efficacious dose. The combination portion should be starting relatively soon too. Since its open label some people should obviously know. The other thing of note is I've noticed Howard Robin likes to keep a sizeable amount of cash (above the level of their debt) and with the appreciation he's had ample opportunity to raise cash. I'd imagine 214 if the data is good is unlikely to pursued alone because of the broad application the question is how early would it be partnered or would the company just be acquired? If AZ had confidence in Movantik would seem like the ideal fit.